Vildagliptin-d3

Vildagliptin-d3

• CAS Number: 1217546-82-1
• UNSPSC Description: Vildagliptin-d3 is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1][2].
• Target Antigen: Apoptosis; Dipeptidyl Peptidase; Ferroptosis; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Apoptosis;Metabolic Enzyme/Protease;Others
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease
• Solubility: 10 mM in DMSO
• Smiles: N(CC(=O)N1[C@](C#N)(CCC1([2H])[2H])[2H])C23CC4(O)CC(C2)CC(C3)C4
• Molecular Weight: 306.42
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Villhauer EB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46(13):2774-89.|[3]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64(2):226-35.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported